Klaria Pharma Holding AB (SE:KLAR)
:KLAR
Top Page
Klaria Pharma Holding AB
(KLAR)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr1.00
▲(63.93% Upside)
Action:ReiteratedDate:04/11/26
The score is held down primarily by very weak financial performance (large ongoing losses, rising cash burn, and negative equity). Technicals are supportive in the near term (price above key moving averages and positive MACD) but are offset by overbought signals (high RSI/Stoch). Valuation provides limited support because the negative P/E reflects unprofitability and there is no dividend yield.
Positive Factors
Proprietary drug-delivery technology
Owning a proprietary mucoadhesive oral film platform is a durable competitive asset: it differentiates product candidates on convenience and administration, creates IP-based barriers, and supports multiple indications or APIs, enabling long-term licensing and product lifecycle value capture.
Negative Factors
Persistent large operating losses
Extremely negative and persistent operating losses undermine the company's ability to self-fund development and signal structural unprofitability. Over time this drives dependence on external capital, increases dilution risk, and weakens negotiating leverage with partners and suppliers.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary drug-delivery technology
Owning a proprietary mucoadhesive oral film platform is a durable competitive asset: it differentiates product candidates on convenience and administration, creates IP-based barriers, and supports multiple indications or APIs, enabling long-term licensing and product lifecycle value capture.
Read all positive factors
Klaria Pharma Holding AB (KLAR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr300.09M
Dividend YieldN/A
Average Volume (3M)401.28K
Price to Earnings (P/E)―
Beta (1Y)2.41
Revenue GrowthN/A
EPS Growth17.42%
CountrySE
Employees4
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.03
Shares Outstanding245,976,150
10 Day Avg. Volume684,621
30 Day Avg. Volume401,283
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr24.00M
Klaria Pharma Holding AB Business Overview & Revenue Model
Company Description
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/A...
How the Company Makes Money
null...
Klaria Pharma Holding AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.00M | 2.25M | 8.45M | 5.87M | 6.11M |
| Gross Profit | 8.98M | 2.25M | 8.45M | 5.87M | -4.85M |
| EBITDA | -14.02M | -19.99M | -20.81M | -44.80M | -39.41M |
| Net Income | -38.90M | -47.75M | -35.78M | -63.77M | -53.53M |
Balance Sheet | |||||
| Total Assets | 40.77M | 57.27M | 72.95M | 120.27M | 118.31M |
| Cash, Cash Equivalents and Short-Term Investments | 342.00K | 598.00K | 1.25M | 16.76M | 25.49M |
| Total Debt | 0.00 | 23.07M | 18.93M | 17.09M | 31.72M |
| Total Liabilities | 44.65M | 53.96M | 31.81M | 44.19M | 48.89M |
| Stockholders Equity | -3.88M | 3.31M | 41.13M | 76.08M | 69.41M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -11.94M | -3.37M | -49.77M | -24.80M |
| Operating Cash Flow | -35.04M | -11.94M | -9.06M | -49.73M | -24.80M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -42.00K | 0.00 |
| Financing Cash Flow | 34.78M | 11.27M | -6.46M | 41.06M | 19.04M |
Klaria Pharma Holding AB Technical Analysis
Positive
0.61
Price Trends
0.88
Positive
0.79
Positive
0.65
Positive
Market Momentum
0.06
Negative
72.79
Negative
94.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KLAR, the sentiment is Positive. The current price of 0.61 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 0.88, and below the 200-day MA of 0.65, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 72.79 is Negative, neither overbought nor oversold. The STOCH value of 94.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:KLAR.
Klaria Pharma Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr641.88M | -60.92 | -48.65% | ― | -60.33% | 58.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr300.09M | -3.17 | -530.21% | ― | ― | 17.42% | |
45 Neutral | kr18.68M | -1.13 | ― | ― | ― | 72.30% | |
44 Neutral | kr168.92M | -4.22 | -90.66% | ― | ― | 15.74% | |
43 Neutral | kr85.69M | -2.13 | -24.83% | ― | ― | ― | |
41 Neutral | kr30.21M | -1.77 | ― | ― | ― | ― |
* Healthcare Sector Average
SE:KLAR
Klaria Pharma Holding AB
1.22
0.14
13.28%
SE:ALZCUR
AlzeCure Pharma AB
1.47
-0.72
-32.72%
SE:VIVE
Vivesto AB
0.08
-0.13
-62.25%
SE:GABA
Gabather AB
0.04
>-0.01
-2.56%
SE:NANEXA
Nanexa AB
3.90
2.60
200.46%
SE:ERMA
Enorama Pharma AB
0.41
-1.72
-80.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.